What Is the Risk of Secondary Cancers in CLL Patients?
From our September 2024 CLL Global Research Foundation town hall featuring CLL Global President, Dr. William Wierda, and Dr. Erin Parry from Dana-Farber Cancer Institute. CLL patient advocate Jeff Folloder moderated the event.
Can Vaccinations Cause a CLL Flare?
From our September 2024 CLL Global Research Foundation town hall featuring CLL Global President, Dr. William Wierda, and Dr. Erin Parry from Dana-Farber Cancer Institute. CLL patient advocate Jeff Folloder moderated the event.
What Are the Signs of Richter’s Transformation?
From our September 2024 CLL Global Research Foundation town hall featuring CLL Global President, Dr. William Wierda, and Dr. Erin Parry from Dana-Farber Cancer Institute. CLL patient advocate Jeff Folloder moderated the event.
CLL Global Virtual Town Hall: September 12, 2024
Experts discussed the latest advances in CLL clinical trials highlighted at the 2021 American Society of Hematology (ASH) meeting, the world’s premier conference in hematology.
CLL Global Research Foundation | Research Updates
Dr. William Wierda discussed the latest research funded by the CLL Global Research Foundation during the Feb 7, 2024 virtual town hall.
How Do You Know When CLL Treatment Should Begin?
Experts responded to a viewer question about the CLL watch & wait period during the Feb 7, 2024 CLL Global Research Foundation virtual town hall.
Understanding What the CLL 10-Year Progression-Free Survival of Ibrutinib Means
Experts explained the meaning of the CLL 10-year progression-free survival of Ibrutinib during the Feb 7, 2024 CLL Global Research Foundation virtual town hall.
Are CLL Patients At-Risk for AML or CML?
Experts responded to a viewer question about the risk of AML and CML during the Feb 7, 2024 CLL Global Research Foundation virtual town hall.
What’s the Outlook for Future CLL Care?
Dr. William Wierda and Dr. Patrick Reville share their hope for the future of CLL care.
CLL Research Updates From ASH 2023
Experts discussed the latest updates from the 2023 American Society of Hematology (ASH) meeting.